Immune Pharmaceuticals appoints Paul Nadler as acting executive VP of R&D and CMO

Israel-based Immune Pharmaceuticals (Nasdaq: IMNP) has appointed Paul Nadler as acting executive vice president of research and development, and chief medical officer.

He will oversee the company’s immunology and oncology pipeline. Prior to this, Dr Nadler has held similar positions at early-stage biotech companies including OSI Pharmaceuticals, Fast Track Systems, Alexion Pharmaceuticals, CGI Pharma, Phylogix, Aveo and Dicerna.

Dr Nadler said: "I am excited about the opportunity to work with Immune Pharmaceuticals at this important inflexion point with the development of bertilimumab. The target for bertilimumab, eotaxin-1, may play a key role in multiple auto-immune and inflammatory diseases. We look forward to data from the phase II clinical trial in bullous pemphigoid in 2015 and data from the phase II clinical trial in ulcerative colitis in 2016. I believe that additional important indications may be selected for further development based on pre-clinical and pilot clinical data and I am excited about future possibilities. In addition, I am hopeful that we will be able to evaluate and capitalize on the great potential of the existing diverse nanomAbs platform to facilitate truly targeted delivery of a variety of active antineoplastic agents to take us beyond earlier generation nano-therapeutics and other conjugate technologies tested thus far."